|Awarded On||February 16, 2022|
|Title||Telomere Maintenance Mechanisms as Prognostic Biomarkers and Therapeutic Targets in Neuroblastoma and Rhabdomyosarcoma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Charles Reynolds|
|Cancer Sites||Brain and Other Nervous System, Sarcoma|
Neuroblastoma and rhabdomyosarcomas are childhood cancers in need of improved therapy. For continual growth cancer cells must maintain the ends of chromosomes (called telomeres) which erode if not maintained by telomere maintenance mechanisms (TMM). The most common TMM uses an enzyme in cells called telomerase which is capable of adding DNA to the ends of chromosomes. Some cancers use a non-telomerase mechanism known as alternate lengthening of telomeres (ALT). We have shown that TMM assays can divide neuroblastoma patients into 3 groups with distinctly different survival; patients with ALT+ tumors have the lowest survival.
This project will continue to work with the national Children's...